Treatment with the investigational next-generation KRAS-G12C inhibitor elisrasib led to clinical benefit in patients with ...

Zoldonrasib ideal for further evaluation in KRAS G12D-mutant disease, expert says ...

Rezatapopt is a first-in-class oral therapy designed to target the TP53 Y220C mutation. This mutation affects the p53 protein ...

The investigational KRAS G12D inhibitor zoldonrasib showed evidence of clinical activity and a favorable safety profile in ...

Ziftomenib was approved by the U.S. Food and Drug Administration (FDA) in November 2025 for the treatment of adult patients with R/R NPM1 -m AML who have no satisfactory alternative treatment options, ...

Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel demonstrated a highly statistically significant improvement versus ...

"We need to focus on getting these drugs to patients quickly," expert says ...

In 2001 scientists studying human language made a breakthrough: by looking at the DNA of a family with a rare speech ...

Two papers published in The New England Journal of Medicine highlight the potential of gene editing for treatment of sickle ...

Pediatric low-grade gliomas (pLGGs) exhibit distinct biological and clinical characteristics compared to adult gliomas, and their treatment strategies differ substantially from those used in adults.

Pediatric low‑grade gliomas (pLGGs) have distinct biology and treatment strategies compared to adult gliomas. These Chinese consensus guidelines ...